TKIs治疗非小细胞肺癌中罕见EGFR 突变的研究进展

Advances in the Treatment of Uncommon EGFR Mutationsin NSCLC with Tyrosine Kinase Inhibitors

酪氨酸激酶抑制剂(TKIs)为目前治疗非小细胞肺癌患者(NSCLC)表皮生长因子受体(EGFR)基因突变的一线用药,非典型EGFR突变病例数较少,且患者个体异质性较高,相关前瞻性临床治疗数据少。本文以德国国家基因组医学网络研究分类为基础,对目前NSCLC中罕见EGFR突变(G719X、S768I、L861Q及其复合突变)的研究现状和TKIs(吉非替尼、阿法替尼和奥希替尼)治疗NSCLC罕见EGFR突变的相关研究进展进行讨论。

Tyrosine kinase inhibitors(TKIs)are currently the first-line drugs for treating epidermal growth factor receptor(EGFR)gene mutations in patients with non-small cell lung cancer(NSCLC).The relevant prospective clinical treatment data on NSCLC with atypical EGFR mutations are few,owing to the small number of cases and the high individual heterogeneity.Based on the classification of the German National Genome Medical Network,the research status of uncommon EGFR mutations(G719X,S768I,L861Q and complex mutations)in NSCLC and the relevant research progress of TKIs(gefitinib,Afatinib and oechtinib)in the treatment of NSCLC with uncommon EGFR mutations were discussed.